Beyond Air Divests NeuroNOS Stake: Milestone Bet on Unproven EEG Biomarker With Zero Validation Data

Pharmacological gap in core symptom management: The only FDA-approved agents for ASD-related symptoms — aripiprazole and risperidone — target irritability rather than core autism features, and carry significant tolerability concerns including sedation, weight gain, dyslipidemia, and suicidal ideation. SSRIs have demonstrated no efficacy against repetitive behaviors in children with ASD and frequently precipitate activating adverse events, while antiepileptic drug efficacy remains inconclusive. Notably, overall efficacy and tolerability of pharmacotherapy in pediatric ASD populations are less favorable than data observed in typically developing children presenting with similar symptoms.

Absence of objective diagnostic and neurobiological markers: The lack of validated biomarkers — such as a blood-based diagnostic test or sensitive neurobiomarkers — impedes both accurate diagnosis and patient stratification. This absence critically hampers the implementation of precision medicine approaches, making it difficult to identify subgroups of young children who may be differentially responsive to specific interventions.

Variability and limitations of behavioral interventions: Early intensive behavioral and developmental interventions (EIBIs/EDIs) yield encouraging but inconsistent outcomes. While IQ gains of 9–15 points and improvements in language development have been reported, effects on core autism symptoms remain highly variable. Study heterogeneity, inconsistent outcome measures, limited long-term follow-up data, and disparities in access further constrain the clinical utility of these approaches.

Workforce and access constraints: Rising ASD patient demand is outpacing the capacity of specialty clinics, creating urgent pressure for autism-competent providers across general practice settings. Families frequently encounter shortages of trained professionals, high therapy costs, insufficient specialist training, limited administrative support, and logistical barriers — all of which impede timely and effective care delivery.

Translational and drug development challenges: Despite expanding knowledge of ASD neurobiology and related neurogenetic syndromes, treatment discovery has remained elusive. Successful translation to human drug development will require precision medicine frameworks incorporating multiple model systems for molecular target selection, robust measures of target engagement, and clinical trial designs capable of addressing patient heterogeneity, statistical power limitations, and the placebo response.